世界のバイオシミラー（バイオ後続品）市場動向：エリトロポエチン、ヒト成長ホルモン、果粒球コロニー刺激因子、モノクローナル抗体など...市場調査レポートについてご紹介

1. Analyst View
2. Research Methodology
3. Biologics Market Outlook to 2020
3.1 Market Size
3.2 Market Segmentation
4. Global Biosimilars Market Outlook 2020
4.1 Market Size
4.2 Market Segmentation by Application
4.2.1 Erythropoietin (EPO)
4.2.2 Human Growth Hormone (HGH)
4.2.3 Granulocyte- Colony Stimulating Factor (G-CSF)
4.2.4 Monoclonal Antibody (mAb)
4.2.5 Insulin
4.2.6 Interferon (IFN)
4.3 Market Segmentation by Geography
4.3.1 Europe
4.3.2 Asia-Pacific
4.3.3 Others
5. Market Drivers and Challenges
5.1 Drivers
5.1.1 Approval of the First Biosimilar in the US Opens the Doors of a Lucrative Market
5.1.2 Shrinking Healthcare Budgets to Carve Way for Biosimilars
5.1.3 Numerous Biologic Patent Expiries Provide Opportunity for Biosimilars
5.2 Challenges
5.2.1 Need for the Development of Manufacturing Capabilities
5.2.2 Greater Litgation Risk
5.2.3 High Cost of Development Accompanied with Low Adoption
5.2.4 Interchangeability/ Substitutability
6. Market Trends and Developments
6.1 Plant based Manufacturing Platforms for Biosimilars
6.2 Developing Economies Emerge as Potential Markets for Biosimilar Production
7. Mergers and Acquisitions
8. Porters Five Forces Model
9. Competitive Landscape
9.1 Market Share of Major Players
9.2 Profiles
9.2.1 Biocad
9.2.2 Celltrion
9.2.3 Dong-A Pharmaceutical Co., Ltd
9.2.4 Hospira
9.2.5 Intas
9.2.6 Sandoz
9.2.7 Stada Arzneimittel
9.2.8 Teva
10. Future Outlook

List of Figures:

Figure 3-1: Global – Biologics Market (Billion US$), 2014-2020
Figure 3-2: Share of Biologics in Sales of Top 100 Pharma Products
Figure 3-3: Global – Biologics Market by Segment (%), 2014
Figure 4-1: Global – Biosimilars Market (Billion US$), 2014-2020
Figure 4-2: Global – Biosimilars Market by Key Segment (%), 2014
Figure 4- 3: Global – Biosimilars Market by Key Segment (%), 2020
Figure 4-4: Global – Erythropoietin Biosimilars Market (Million US$), 2014 & 2020
Figure 4-5: Global – HGH Biosimilars Market (Million US$), 2014 & 2020
Figure 4-6: Global – G-CSF Biosimilars Market (Million US$), 2014 & 2020
Figure 4-7: Global – mAb Biosimilars Market (Million US$), 2014 & 2020
Figure 4-8: Global – Insulin Biosimilars Market (Million US$), 2014 & 2020
Figure 4-9: Global – Interferon Biosimilars Market (Million US$), 2014 & 2020
Figure 4-10: Europe – Biosimilars Market (Million US$), 2014-2020
Figure 4-11: Europe – Biosimilars Market by Country (%), 2014
Figure 4-12: Asia – Pacific – Biosimilars Market (Billion US$), 2014-2020
Figure 4-13: Asia – Pacific – Biosimilars Market by Country (%), 2014
Figure 4-14: Others – Biosimilars Market (Billion US$), 2014-2020
Figure 5-1: World’s Best Selling Biologics and their Patent Expiry in the US
Figure 9-1: Market Share of Major Players in the Biosimilar Industry, 2014
Figure 9-2: Hospira – Breakdown of Revenue by Geographic Segment (%), 2013
Figure 9-3: Hospira – Breakdown of Revenue by Industry Segment (%), 2013
Figure 9-4: Sandoz – Global Sales (Billion USD), 2011-2013
Figure 9-5: Sandoz – Breakdown of Revenue by Geographic Segment (Billion USD), 2011-2013

List of Tables:

Table 4-1: Global – Patent Expiry Status of EPOs
Table 4-2: Global – Biosimilar EPOs Approved for Marketing
Table 4-3: Global – Biosimilar EPOs in Pipeline
Table 4-4: Global – Biosimilar HGH Approved for Marketing
Table 4-5: Global – Biosimilar HGH in Pipeline
Table 4-6: Global – Biosimilar G-CSF Approved for Marketing
Table 4-7: Global Biosimilar G-CSF Market – Key Players by Rank
Table 4-8: Global – Biosimilar G-CSF in Pipeline
Table 4-9: Global – Patent Expiry Status of G-CSF
Table 4-10: Global – Biosimilar mAbs Approved for Marketing
Table 4-11: Global Biosimilar mAb Market – Key Players by Rank
Table 4-12: Global – Biosimilar mAbs in Pipeline
Table 4-13: Global – Patent Expiry Status of mAbs
Table 4-14: Global – Biosimilar Insulin Approved for Marketing
Table 4-15: Global Biosimilar Insulin Market – Key Players by Rank
Table 4-16: Global – Biosimilar Insulin in Pipeline
Table 4-17: Global – Patent Expiry Status of Insulin
Table 4-18: Global – Biosimilar Interferons Approved for Marketing
Table 4-19: Global – Biosimilar Interferons in Pipeline
Table 4-20: Global – Patent Expiry Status of Interferons
Table 7-1: Global – Major M&A Activity in the Past Year
Table 9-1: Biocad – Biosimilars Approved for Marketing
Table 9-2: Biocad – Biosimilars in Pipeline
Table 9-3: Biocad – Strengths & Weaknesses
Table 9-4: Celltrion – Key Financials (Million KRW), 2011-2013
Table 9-5: Celltrion – Biosimilars Approved for Marketing
Table 9-6: Celltrion – Biosimilars in Pipeline
Table 9-7: Celltrion – Strengths & Weaknesses
Table 9-8: Dong-A Pharmaceutical – Key Financials (Billion Won), 2011-2013
Table 9-9: Dong-A Pharmaceutical – Biosimilars in Pipeline
Table 9-10: Dong-A Pharmaceutical – Strengths & Weaknesses
Table 9-11: Hospira – Key Financials (Million Dollars), 2011-2013
Table 9-12: Hospira – Biosimilars Approved for Marketing
Table 9-13: Hospira – Biosimilars in Pipeline
Table 9-14: Hospira – Strengths & Weaknesses
Table 9-15: Intas – Biosimilars Approved for Marketing
Table 9-16: Intas – Biosimilars in Pipeline
Table 9-17: Intas – Strengths & Weaknesses
Table 9-18: Sandoz – Biosimilars Approved for Marketing
Table 9-19: Sandoz – Biosimilars in Pipeline
Table 9-20: Sandoz – Strengths & Weaknesses
Table 9-21: Stada – Biosimilars Approved for Marketing
Table 9-22: Stada – Biosimilars in Pipeline
Table 9-23: Stada – Strengths & Weaknesses
Table 9-24: Teva – Biosimilars Approved for Marketing
Table 9-25: Teva – Strengths & Weaknesses